The AXAGIST phase 2 trial aimed to investigate the synergy of axitinib and avelumab in advanced GIST after standard therapy failure. The primary endpoint was to determine PFS. Researchers noted significant efficacy and long-term benefit from the axitinib-avelumab combination in pretreated GIST. The development of tyrosine kinase inhibitors (TKIs) has significantly advanced the […]...